News ESC: Study says GLP-1s treat heart failure AND cut emissions Add a beneficial impact on climate change to the long list of benefits being attributed to GLP-1 agonist medicines.
News Nykode changes tack after Roche exits partnership Hit by the loss of a partnership with Roche's Genentech unit last year, Norway's Nykode has narrowed its R&D focus.
News Regeneron preps filings for myasthenia gravis drug Regeneron could be just a few months away from filing for a myasthenia gravis drug that can be dosed just once every three months.
News Diabetics on Lilly's orforglipron shed 10.5% of their weight Eli Lilly has reported the results of a third phase 3 trial of oral weight-loss therapy orforglipron, clearing the way for filings before year-end.
News Rumour partly confirmed as AbbVie acquires Gilgamesh drug Reports of AbbVie's interest in Gilgamesh Pharma were true, as the companies have agreed a $1.2bn acquisition deal for a psychedelic depression drug.
News Argenx poised to expand Vyvgart market off new phase 3 data New data could expand the label of argenx's Vyvgart to include AChR-Ab seronegative patients, ~20% of gMG patients whose current options are limited.
News Astellas pays $285m for Audax cancer drug, and other deals Astellas takes an option on a cancer immunotherapy developed by Audax for up to $1.34bn, with Gilead and Teva also adding to their pipelines.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
